Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.55 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.55 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | GRM8 | O00222 | 1/20 | 0.55 |
| ▸ | GRM6 | O15303 | 1/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL31070222 | 1.00 | — | — | |
| D-Aspartate SCHEMBL145539 | 1.00 | — | — | |
| Aspartic Acid SCHEMBL31673497 | 1.00 | — | — | |
| Aspartic Acid SCHEMBL11065189 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL1526976 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL3230 | 1.00 | — | — | |
| D-Aspartate SCHEMBL31235712 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL11065185 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL3231 | 1.00 | — | — | |
| Aspartic Acid SCHEMBL31673507 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471149-B2 | Stabilized vancomycin formulations | INSMED INCORPORATED (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2925298-B1 | STABILIZED VANCOMYCIN FORMULATIONS | INSMED INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20190022232-A1 | STABILIZED VANCOMYCIN FORMULATIONS | INSMED INCORPORATED | 2019-01-24 | — | — | US | disclosed |
| US-10124066-B2 | Stabilized vancomycin formulations | INSMED INCORPORATED (US) | 2018-11-13 | — | — | US | disclosed |
| US-20150314002-A1 | STABILIZED VANCOMYCIN FORMULATIONS | INSMED INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20110200842-A1 | STRESS-REDUCED NI-P/PD STACKS FOR BONDABLE WAFER SURFACES | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| WO-2011064237-A1 | CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20110077362-A1 | Branched Polymers | NEKTAR THERAPEUTICS (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2177646-B1 | Stress-reduced Ni-P/Pd stacks for bondable wafer surfaces | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-7872072-B2 | Branched water soluble polymers containing at least two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent; drugs/polymer conjugates/;bioavailability | NEKTAR THERAPEUTICS (US) | 2011-01-18 | — | — | US | disclosed |
| US-5916761-A | DETERMINING ADENOSINE 5' DIPHOSPHATE (ADP) CONTAINED IN A LIQUID SAMPLE BY MEANS OF AN ENZYMATIC REACTION | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471149-B2 | Stabilized vancomycin formulations | CETP, PCSK9, HDLBP | GRIK1 2799/4885GRIK2 3022/4885GRM1 3381/4885 |
| US-10124066-B2 | Stabilized vancomycin formulations | CETP, PCSK9, HDLBP | GRIK1 2799/4885GRIK2 3022/4885GRM1 3381/4885 |
| US-20150314002-A1 | STABILIZED VANCOMYCIN FORMULATIONS | CETP, PCSK9, HDLBP | GRIK1 2799/4885GRIK2 3022/4885GRM1 3381/4885 |
| US-20190022232-A1 | STABILIZED VANCOMYCIN FORMULATIONS | CETP, PCSK9, HDLBP | GRIK1 2799/4885GRIK2 3022/4885GRM1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.